<DOC>
	<DOCNO>NCT00965276</DOCNO>
	<brief_summary>This study examine relationship protein call pAKT survival breast cancer patient one positive axillary lymph node . Akt play role cell survival , tumor formation , development drug resistance . The study use tumor tissue obtain 2,000 patient enrolled National Surgical Adjuvant Breast Bowel Project study evaluate whether add drug paclitaxel ( Taxol ( Registered Trademark ) ) treatment regimen doxorubicin ( Adriamycin ( Registered Trademark ) ) cyclophosphamide ( Cytoxan ( Registered Trademark ) ) improve disease-free survival overall survival patient node-positive breast cancer . The current study measure level pAkt tissue correlate result clinical outcome see pAkt level associate improved patient survival .</brief_summary>
	<brief_title>Relationship pAKT Survival Patients With Node-Positive Breast Cancer</brief_title>
	<detailed_description>Taxanes ( paclitaxel docetaxel ) emerge powerful chemotherapeutics breast cancer past decade . The B-28 clinical trial National Surgical Adjuvant Breast Bowel Project ( NSABP ) assess efficacy add paclitaxel doxorubicin/cyclophosphamide regimen treatment patient axillary node positive breast cancer . The primary aim B-28 determine whether four cycle paclitaxel ( Taxol ( Registered Trademark ) ) ( T ) follow four cycle postoperative Doxorubicin ( adriamycin ( Registered Trademark ) ( A ) cyclophosphamide ( C ) effectively prolong disease-free survival ( DFS ) survival ( S ) four cycle AC alone patient operable breast cancer one histologically positive axillary lymph node . The B-28 clinical trial tissue microarray consist specimens 2,000 case enrol . The tissue microarray set ideal platform evaluate predictive marker doxorubicin and/or paclitaxel response resistance . Akt , serine/threonine protein kinase regulate phosphatidylinositol 3-kinase ( PI3K ) , importance cell survival , tumorigenesis , recently show , chemoresistance . It confer survival advantage cell transduce signal growth factor receptor activate PI3K . The primary aim study evaluate whether level phosphorylated AKT associate disease-free overall survival patient node-positive breast cancer treat AC and/or AC follow paclitaxel .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>INCLUSION CRITERIA The NSABP B28 trial enrol woman 1995 1998 operable breast cancer pathologically positive axillary lymph node .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 14, 2010</verification_date>
	<keyword>Adjuvant Therapy</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Chemoresistance</keyword>
	<keyword>Serine/Threonine Kinase</keyword>
	<keyword>Cell Survival</keyword>
	<keyword>Breast Cancer</keyword>
</DOC>